Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...

As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer ...

ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major brokerages Oppenheimer and ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives. Shares of the ...

Piper Sandler analyst Joseph Catanzaro downgraded the rating on ESSA Pharma (EPIX – Research Report) to a Hold today, setting a price ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

JonesResearch analyst Soumit Roy downgraded Essa Pharma (EPIX) to Hold from Buy with no price target after the board decided to terminate all trials to conserve cash. The firm, which says “we ...

ESSA Pharma has a twelve month low of $1.40 and a twelve month high of $11.67. The company has a market cap of $75.43 million, a price-to-earnings ratio of -2.74 and a beta of 1.84.

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...